大博医疗(002901) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥665,815,103.16, representing a year-on-year increase of 17.82%[5] - Net profit attributable to shareholders was ¥180,387,474.59, up 77.49% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥123,275,408.71, an increase of 38.44% year-on-year[5] - Total operating revenue for Q3 2025 reached ¥1,876,254,824.66, an increase of 22.7% compared to ¥1,529,257,676.10 in Q3 2024[19] - Net profit for Q3 2025 was ¥448,823,669.30, up 70.5% from ¥263,149,336.98 in Q3 2024[20] - Basic earnings per share for Q3 2025 were ¥1.0444, compared to ¥0.5794 in Q3 2024, reflecting a significant increase[21] - Operating profit for Q3 2025 was ¥514,358,734.98, a rise of 78.2% from ¥288,603,968.09 in Q3 2024, indicating improved operational efficiency[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,554,839,533.75, reflecting a growth of 3.08% from the end of the previous year[5] - Total assets as of Q3 2025 amounted to ¥4,554,839,533.75, up from ¥4,418,929,603.41 in the previous year[18] - Total liabilities decreased to ¥1,117,390,868.79 from ¥1,237,317,657.89 year-over-year, indicating improved financial stability[18] - Total current assets increased to ¥2,986,575,438.17 from ¥2,811,610,722.46[16] - Trade receivables rose to ¥303,506,186.43 from ¥235,579,112.44, indicating a growth of approximately 28.8%[16] - Inventory remains stable at ¥1,271,571,730.77, slightly down from ¥1,272,779,370.13[16] - Fixed assets decreased to ¥1,065,320,071.43 from ¥1,101,179,566.26[16] Equity and Shareholder Information - The total equity attributable to shareholders rose to ¥3,336,569,852.45, marking an increase of 8.37% from the previous year[5] - The company's total equity increased to ¥3,437,448,664.96 in Q3 2025, compared to ¥3,181,611,945.52 in Q3 2024, showing strong growth in shareholder value[18] - Total number of common shareholders at the end of the reporting period is 22,765[12] - The largest shareholder, Guangxi Dabo Business Communication Venture Capital Co., Ltd., holds 23.46% of shares, totaling 97,124,098 shares[12] - The top ten shareholders account for a significant portion of the company's equity, with the top three holding over 63% combined[12] - The company has a total of 7,409,900 shares held in the repurchase special securities account, representing 1.79% of total shares[13] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[13] Cash Flow and Investments - The company reported a significant increase in cash flow from operating activities, with a net amount of ¥468,292,048.05, up 124.26% year-to-date[5] - Operating cash inflow for the current period was $2,125,257,418.09, an increase of 22.3% from $1,737,849,496.04 in the previous period[23] - Net cash flow from operating activities was $468,292,048.05, up 124.5% from $208,812,403.51 year-over-year[23] - Cash outflow from investing activities totaled $1,605,258,126.37, an increase of 31.3% compared to $1,222,498,801.80 in the previous period[24] - Net cash flow from investing activities was -$319,058,783.65, a decline from a positive $94,896,830.93 in the previous period[24] - Cash inflow from financing activities was $77,570,176.00, up from $67,861,081.00 in the previous period[24] - Net cash flow from financing activities was -$338,987,025.69, an improvement from -$418,803,870.64 year-over-year[24] - The ending cash and cash equivalents balance was $60,131,962.39, down from $159,891,883.23 in the previous period[24] - Cash received from sales of goods and services was $2,046,889,518.51, compared to $1,646,466,291.02 in the previous period[23] - Total cash outflow for employee payments was $620,292,294.94, an increase from $543,317,049.92 in the previous period[23] - Cash received from other operating activities was $75,800,724.44, slightly down from $80,759,720.17 in the previous period[23] Research and Development - Research and development expenses for Q3 2025 were ¥250,245,754.07, an increase of 16.6% from ¥214,640,411.75 in Q3 2024, highlighting ongoing investment in innovation[19] Fair Value and Government Subsidies - The fair value changes of financial assets resulted in a profit of ¥37,714,385.71, a substantial increase of 3523.41% compared to the previous year[9] - The company received government subsidies totaling ¥30,763,148.25 during the reporting period, contributing to its financial performance[6]